According to a research study conducted by the National Institute for Clinical Excellence (NICE) in UK, Somatropin has been found to be clinically- and cost-effective in treating illnesses associated with growth hormone (GH) deficiency. Such illnesses include Turner syndrome and Prader-Willi syndrome.
NICE understands and still recommends that treatment of GH deficiency should be initiated and monitored by pediatricians with specialization in the management of growth hormone disorders. However, they also recognize the possibility of a faster and better monitoring if all medical practitioners agree to provide maintenance care under a “shared-care” agreement.
Nevertheless, the majority of medical practitioners, especially in the UK, appreciate NICE’s efforts in developing this new research for the treatment of GH deficiency.